Expertise in
2
conditions

Dr. Joseph Chao

Hematology
City Of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
City Of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, 
Duarte, CA 

Overview

Joseph Chao is a Hematologist practicing medicine in Duarte, California.

Dr. Chao is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Junction Cancer, PIK3CA-Related Overgrowth Spectrum, Agranulocytosis, Endoscopy, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 112 peer reviewed articles and participating in 15 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

City of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Drugs: INBRX-109 Tetravalent DR5 Agonist Antibody, Carboplatin, Cisplatin, Pemetrexed, 5-Fluorouracil, Irinotecan
Study Phase: Phase 1
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination With FOLFIRI in GI Malignancies With a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination With FOLFIRI in GI Malignancies With a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Procedure, Drug
Study Drugs: Elimusertib, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium
Study Phase: Phase 1
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Irinotecan
Study Phase: Phase 2
A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2026
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas
A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas
Enrollment Status: Active_not_recruiting
Publish Date: June 23, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Carboplatin, Lenvatinib Mesylate, Paclitaxel, Pembrolizumab
Study Phase: Phase 2
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Biological, Drug
Study Drugs: Olaparib, Ramucirumab
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
Enrollment Status: Terminated
Publish Date: September 04, 2024
Intervention Type: Genetic
Study Phase: Phase 2
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of TPX4589 in Patients With Claudin(CLDN)18.2-Positive Advanced Solid Tumors
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of TPX4589 in Patients With Claudin(CLDN)18.2-Positive Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 17, 2024
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

112 Total Publications

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 11, 2025
Similar Doctors
Expertise in
55
conditions
Dr. Stephen J. Forman
Hematology | Oncology
Expertise in
55
conditions
Dr. Stephen J. Forman
Hematology | Oncology
Referral may be required

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
888-304-3959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Forman is a Hematologist and an Oncologist practicing medicine in Duarte, California. Dr. Forman is highly rated in 55 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Steven T. Rosen, M.D.

1500 Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Rosen is a Hematologist practicing medicine in Duarte, California. Dr. Rosen is highly rated in 22 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
11
conditions
Dr. Thomas D. Coates
Hematology | Oncology
Expertise in
11
conditions
Dr. Thomas D. Coates
Hematology | Oncology
Referral may be required

Office

4650 W Sunset Blvd # 54, 
Los Angeles, CA 
 (18.4 miles away)
323-361-4624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Coates is a Hematologist and an Oncologist practicing medicine in Los Angeles, California. Dr. Coates is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Joseph Chao

How do I make an appointment with Dr. Joseph Chao?

You can book an appointment with Dr. Joseph Chao by calling their office at 626-256-4673. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph Chao a top-rated expert for Gastroesophageal Junction Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph Chao is classified as an Distinguished expert for Gastroesophageal Junction Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph Chao specialize in?

While Dr. Joseph Chao is a Hematology, they have specific expertise in Gastroesophageal Junction Cancer, PIK3CA-Related Overgrowth Spectrum, and Agranulocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Joseph Chao participate in research or clinical trials?

Yes. Dr. Joseph Chao has published 112 articles and abstracts on conditions like Gastroesophageal Junction Cancer. You can view a list of Dr. Joseph Chao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joseph Chao accept my insurance?

Dr. Joseph Chao accepts most major insurance plans, including Aetna and Medicaid. We recommend calling the office directly at 626-256-4673 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chao's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile